Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia

Boehringer IngelheimBoehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors. An "orphan receptor" is structurally related to a family of proteins that are known to act as functional cell-surface receptors but whose ligand has not yet been identified.

Arena will provide Boehringer Ingelheim exclusive rights to its internally discovered, novel compounds and intellectual property for an orphan CNS receptor. The companies will jointly conduct research to identify additional drug candidates that are suitable for continued research and development as therapeutic compounds for various disease indications. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.

According to the World Health Organization, mental illness - together with substance abuse disorders - remains the leading cause of disability worldwide. At least 450 million people(1) suffer from mental health problems. The global economic burden of mental illness is larger than for cancer, cardiovascular disease or diabetes and continues to grow - with significant health, social and economic consequences. As currently available treatment options leave many patients unsatisfactorily treated, more effective medicines for mental diseases are urgently needed.

"This agreement reflects our new corporate focus to enter into collaboration opportunities at various stages of development," said Harry F. Hixson, Jr., Arena's interim Chief Executive Officer. "Collaborations are an essential part of our drug discovery and development efforts, so we are pleased to be part of this shared goal to identify novel drugs targeting an orphan CNS receptor with Boehringer Ingelheim, who possesses demonstrated capabilities in research, development, manufacturing, and marketing of pharmaceutical products."

"Together with our research partners in neuroscience, we are targeting brain circuits underlying major untreated symptom domains in our CNS focus areas of Alzheimer's disease, schizophrenia, and depression. We are delighted to enter into this new collaboration with Arena, who have recognized expertise in orphan CNS GPCR drug discovery and development," said Corporate Senior Vice President Clive R. Wood, Head of Discovery Research of Boehringer Ingelheim. "We believe that this alliance with Arena will allow us to deliver innovative, new medicines for the treatment of patients with psychiatric diseases such as schizophrenia and contribute to our vision of helping the millions of people with mental illness, to live fuller, more independent lives, for longer."

The new partnership combines Arena's expertise in GPCR focused drug discovery and development with Boehringer Ingelheim's unique approach to CNS research and development and its proven capabilities in bringing novel medications of high therapeutic value to the market in areas of high unmet medical need.

The collaboration is part of Boehringer Ingelheim’s commitment to researching and developing new and more effective treatments for psychiatric diseases and their symptoms.

Under the terms of the agreement, Arena is eligible to receive payments up to $262 million in success milestones in case of full commercial success of multiple drug products, including an upfront payment and research funding. In addition, Arena is eligible to receive tiered royalties on future sales of products that arise from the collaboration. Further details of the agreement were not disclosed.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

About Arena Pharmaceuticals
Arena embraces the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's focus is discovering, developing and commercializing drugs to address unmet medical needs, and BELVIQ® (lorcaserin HCl) is Arena’s first internally discovered drug approved for marketing. Arena has US operations located in San Diego, California, and operations outside of the United States, including its commercial manufacturing facility, located in Zofingen, Switzerland.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

1. Saraceno, S. The WHO World Health Report 2001 on mental health. Epidemiologia e Psichiatria Sociale, June 2002; Vol. 11, Iss. 2:83-87.

Most Popular Now

Merck invests € 250 million in production value ch…

Merck, a leading science and technology company, today inaugurated its € 170 million Nantong pharmaceutical plant, which is dedicated to producing high-quality pharmaceut...

Read more

Roche launches imCORE, a global network of cancer …

Roche (SIX: RO, ROG; OTCQX: RHHBY) has launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the...

Read more

New research shows promise for immunotherapy as HI…

Immunotherapy has revolutionized treatment options in oncology, neurology, and many infectious diseases and now there is fresh hope that the same method could be used to ...

Read more

15th Annual eyeforpharma Philadelphia 2017

20 - 21 April 2017, Philadelphia, USA. It's eyeforpharma Philadelphia's 15th year; already the largest, most senior and most influential forum for commercial pharma exec...

Read more

Pancreatic cancer set to become third biggest canc…

The number of deaths from pancreatic cancer will overtake breast cancer mortality rates in the EU in 2017, a study has found. The findings, recently presented at UEG Week...

Read more

Merck wins R&D 100 Award for top invention

Merck, a leading science and technology company, received a prestigious R&D 100 Award for its Sanger Arrayed Lentiviral CRISPR Libraries - the first of its kind CRISPR li...

Read more

Regorafenib from Bayer submitted to health authori…

Bayer has announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe, fo...

Read more

Researchers discover way to inhibit major cancer g…

Researchers at the University of Illinois at Chicago have identified a new way to block the action of genetic mutations found in nearly 30 percent of all cancers. Mutatio...

Read more

Genetically engineering disease-fighting cells

The human body produces T cells to recognize and fight disease. Each T cell has a unique T cell receptor (or TCR) on its surface that surveils small fragments of proteins...

Read more

New European study highlights differing priorities…

Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been publishe...

Read more

Benzodiazepine and related drug use increases hip …

The use of benzodiazepines and related drugs increases the risk of hip fracture by 43% in persons with Alzheimer's disease, according to a new study from the University o...

Read more

Among antidementia drugs, memantine is associated …

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]